Davis AI | $5,500,000 | (May 8, 2026)
Balcony | $12,700,000 | (May 8, 2026)
Jetty | $2,000,000 | (May 8, 2026)
Certified by Founder
Lodge
Delphia Therapeutics
start up
United States
- Cambridge, Massachusetts
- 07/05/2024
- Series A
- $67,000,000
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.
- Industry Biotechnology Research
- Website https://www.delphiatx.com/
- LinkedIn https://www.linkedin.com/company/delphia-therapeutics/
ParcelBio | $13,000,000 | (May 8, 2026)
Jesse & Ben's | $10,000,000 | (May 8, 2026)
SageOx | $15,000,000 | (May 8, 2026)
CodeWords | $9,000,000 | (May 8, 2026)
Ethos | $22,750,000 | (May 8, 2026)
illoca | $13,000,000 | (May 8, 2026)
Lithosquare | $25,000,000 | (May 8, 2026)
Jurisphere.ai | $2,200,000 | (May 8, 2026)
OpsMill | $14,000,000 | (May 8, 2026)